DN-VCP confers a functional inhibition of VCP in the heart through competitively interfering EN-VCP’s ATPase activity and unbalancing the VCP’s co-factors interaction and nuclear translocation, leading to cardiomyopathy and dysfunction during the aging transition. This evidence concerns the gene VCP and cardiomyopathy.